Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity

Basit Öğe Kaydı
dc.authoridKucukarda, Ahmet/0000-0001-7399-2360
dc.authoridSayin, Sezin/0000-0001-7892-5992
dc.authorwosidKüçükarda, Ahmet/AGF-2120-2022
dc.authorwosidAykan, Musa Barış/AEK-4253-2022
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorSayin, Sezin
dc.contributor.authorGokyer, Ali
dc.contributor.authorAykan, Musa Baris
dc.contributor.authorKaradurmus, Nuri
dc.contributor.authorCicin, Irfan
dc.date.accessioned2024-06-12T10:52:45Z
dc.date.available2024-06-12T10:52:45Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractLay abstract Immune checkpoint inhibitors are used with increasing frequency in cancer therapy. New side effects associated with these drugs have been identified. Air accumulation between the pleural membranes, which envelop the lungs and protect them in the ventilation function, without trauma may occur after using these drugs. We present here two cases that were treated with these drugs and developed this side effect. Patients with newly developed shortness of breath during this treatment should be careful about side effects such as this. Background: We present two cases of secondary pneumothorax after immunotherapy in two different clinics. Case summary: A 25-year old female patient with metastatic osteosarcoma, treated with atezolizumab. Grade 2 pneumonitis developed twice in the first year. Treatment was continued after recovery and areas of pneumonitis and pneumothorax were observed on computed tomography. No other reason could be found to cause pneumothorax. Pneumothorax resorbed spontaneously during follow-up. A 36-year old female patient treated with nivolumab for metastatic renal cell carcinoma (RCC), areas of pneumonitis and pneumothorax were only found as the cause of dyspnea. After treatment, remission was achieved on computed tomography findings. Pneumothorax was detected for the second time during continued therapy, and immunotherapy stopped permanently. Conclusion: These cases, indicate that immunotherapy can cause secondary immune-related pneumothorax based on immune pneumonitis.en_US
dc.identifier.doi10.2217/imt-2020-0233
dc.identifier.endpage570en_US
dc.identifier.issn1750-743X
dc.identifier.issn1750-7448
dc.identifier.issue7en_US
dc.identifier.pmid33820440en_US
dc.identifier.scopus2-s2.0-85104876313en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage565en_US
dc.identifier.urihttps://doi.org/10.2217/imt-2020-0233
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18815
dc.identifier.volume13en_US
dc.identifier.wosWOS:000637016900001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFuture Medicine Ltden_US
dc.relation.ispartofImmunotherapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtezolizumaben_US
dc.subjectImmune-Check Point Inhibitorsen_US
dc.subjectImmune-Related Pneumonitisen_US
dc.subjectImmunotherapyen_US
dc.subjectNivolumaben_US
dc.subjectSecondary Pneumothoraxen_US
dc.titleSecondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu